Ixabepilone for the treatment of breast cancer

Annals of Medicine

Volumn 43, Issue 6, 2011, Pages 477-486

  Alvarez, Ricardo H ^a   Valero, Vicente ^a   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Metastatic breast cancer; novel antimicrotubular agents; treatment of advanced breast cancer

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; DEOXYCYTIDINE; DRUG DERIVATIVE; EPOTHILONE DERIVATIVE; FLUOROURACIL; IXABEPILONE; TAXOID;

BREAST TUMOR; DRUG RESISTANCE; FEMALE; HUMAN; METASTASIS; PATHOLOGY; REVIEW;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DEOXYCYTIDINE; DRUG RESISTANCE, NEOPLASM; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; NEOPLASM METASTASIS; TAXOIDS;

EID: 84855568443     PISSN: 07853890     EISSN: 13652060     Source Type: Journal    
DOI: 10.3109/07853890.2011.579151     Document Type: Article

References (64)

1. American Cancer Society, 2007. Breast Cancer Facts & Figures 2007–2008. Atlanta, Georgia: American Cancer Society. www.cancer.org/downloads/STT/BCFF-Final.pdf (accessed in June 2009).
2. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007; 57: 43 – 66.
3. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277 – 300.
4. Arriagada R, Spielmann M, Koscielny S, Le Chevalier T, Delozier T, Ducourtieux M,. Patterns of failure in a randomized trial of adjuvant chemotherapy in postmenopausal patients with early breast cancer treated with tamoxifen. Ann Oncol. 2002; 13: 1378 – 86.
5. Jemal A, Siegel R, Ward E,. Cancer statistics, 2008. CA Cancer J Clin. 2008; 58: 71 – 96.
6. Ravdin P, Cronin KA, Howlader N, Berg CD, Chlebowski R, Feuer EJ,. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med. 2007; 356: 1670 – 4.
7. Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004; 100: 44 – 52.
8. Fumoleau P, Delgado FM, Delozier T, Monnier A, Gil Delgado MA, Kerbrat P,. Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy. J Clin Oncol. 1993; 11: 1245 – 52.
9. Livingston RB, Ellis GK, Gralow JR, Williams MA, White R, McGuirt C,. Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1997; 15: 1395 – 400.
10. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A,. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol. 2008; 26: 3950 – 7.
11. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C,. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999; 17: 485 – 93.
12. Remis RS, O'Shaughnessy MV, Tsoukas C, Growe GH, Schechter MT, Palmer RW,. HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate. CMAJ. 1990; 142: 1247 – 54.
13. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P,. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23: 7794 – 803.
14. Low JA, Wedam SB, Lee JJ, Berman AW, Brufsky A, Yang SX,. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer. J Clin Oncol. 2005; 23: 2726 – 34.
15. Thomas E, Tabernero J, Fornier M, Conte P, Fumoleau P, Lluch A,. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol. 2007; 25: 3399 – 406.
16. Perez EA, Lerzo G, Pivot X, Thomas E, Vahdat L, Bosserman L,. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2007; 25: 3407 – 14.
17. Roche H, Yelle L, Cognetti F, Mauriac L, Bunnell C, Sparano J,. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol. 2007; 25: 3415 – 20.
18. Horwitz SB. Mechanism of action of taxol. Trends Pharmacol Sci. 1992; 13: 134 – 6.
19. Marcus AI, Moore RC, Cyr RJ. The role of microtubules in guard cell function. Plant Physiol. 2001; 125: 387 – 95.
20. Westermann S, Weber K. Post-translational modifications regulate microtubule function. Nat Rev Mol Cell Biol. 2003; 4: 938 – 47.
21. Lee G, Rook SL. Expression of tau protein in non-neuronal cells: microtubule binding and stabilization. J Cell Sci. 1992; 102 (Pt 2): 227 – 37.
22. Bollag DM, McQueney PA, Zhu J, Hensens O, Koupal L, Liesch J,. Epothilones, a new class of microtubule-stabilizing agents with a taxol-like mechanism of action. Cancer Res. 1995; 55: 2325 – 33.
23. Hofle G. The epothilones: an outstanding family of anti-tumor agents. General aspects. Fortschr Chem Org Naturst. 2009; 90: 5 – 28.
24. Lee FY, Borzilleri R, Fairchild CR, Kim SH, Long BH, Reventos-Suarez C,. BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001; 7: 1429 – 37.
25. Goodin S, Kane MP, Rubin EH. Epothilones: mechanism of action and biologic activity. J Clin Oncol. 2004; 22: 2015 – 25.
26. Cortes J, Baselga J. Targeting the microtubules in breast cancer beyond taxanes: the epothilones. Oncologist. 2007; 12: 271 – 80.
27. Lee FY, Smykla R, Johnston K, Menard K, McGlinchey K, Peterson RW,. Preclinical efficacy spectrum and pharmacokinetics of ixabepilone. Cancer Chemother Pharmacol. 2009; 63: 201 – 12.
28. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev. 2008; 34: 378 – 90.
29. Nicolaou KC, Winssinger N, Pastor J, Ninkovic S, Sarabia F, He Y,. Synthesis of epothilones A and B in solid and solution phase. Nature. 1997; 387: 268 – 72.
30. Chou TC, O'Connor OA, Tong WP, Guan Y, Zhang ZG, Stachel SJ,. The synthesis, discovery, and development of a highly promising class of microtubule stabilization agents: curative effects of desoxyepothilones B and F against human tumor xenografts in nude mice. Proc Natl Acad Sci U S A. 2001; 98: 8113 – 8.
31. Kamath AV, Chang M, Lee FY,. Preclinical pharmacokinetics and oral bioavailability of bms-310705, a novel epothilone b analog. Cancer Chemother Pharmacol. 2005; 56: 145 – 53.
32. Szakacs G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov. 2006; 5: 219 – 34.
33. Galmarini CM, Kamath K, Vanier-Viornery A, Hervieu V, Peiller E, Falette N,. Drug resistance associated with loss of p53 involves extensive alterations in microtubule composition and dynamics. Br J Cancer. 2003; 88: 1793 – 9.
34. Bonnet C, Boucher D, Lazereg S, Pedrotti B, Islam K, Denoulet P,. Differential binding regulation of microtubule-associated proteins MAP1A, MAP1B, and MAP2 by tubulin polyglutamylation. J Biol Chem. 2001; 276: 12839 – 48.
35. Dumontet C, Sikic BI. Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. J Clin Oncol. 1999; 17: 1061 – 70.
36. Rouzier R, Rajan R, Wagner P, Hess KR, Gold DL, Stec J,. Microtubule-associated protein tau: a marker of paclitaxel sensitivity in breast cancer. Proc Natl Acad Sci U S A. 2005; 102: 8315 – 20.
37. Lee FY, Borzilleri R, Fairchild CR, Kamath A, Smykla R, Kramer R,. Preclinical discovery of ixabepilone, a highly active antineoplastic agent. Cancer Chemother Pharmacol. 2008; 63: 157 – 66.
38. Gerth K, Bedorf N, Hofle G, Irschik H, Reichenbach H. Epothilons A and B: antifungal and cytotoxic compounds from Sorangium cellulosum (Myxobacteria). Production, physico-chemical and biological properties. J Antibiot (Tokyo). 1996; 49: 560 – 3.
39. McDaid HM, Mani S, Shen HJ, Muggia F, Sonnichsen D, Horwitz SB. Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. Clin Cancer Res. 2002; 8: 2035 – 43.
40. Lee FY, Borzilleri R, Fairchild CR,. Bms-247550: A novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res. 2001; 7: 1429 – 37.
41. Aghajanian C, Burris HA 3rd, Jones S, Spriggs DR, Cohen MB, Peck R,. Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas. J Clin Oncol. 2007; 25: 1082 – 8.
42. Ixempra Kit (ixabepilone) for injection: US prescribing information [database on the Internet]. Princeton (NJ): Bristoy-Myers Squibb Company; 2009.
43. Valero V, Jones SE, Von Hoff DD, Booser DJ, Mennel RG, Ravdin PM,. A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. J Clin Oncol. 1998; 16: 3362 – 8.
44. Green MC, Buzdar AU, Smith T, Ibrahim NK, Valero V, Rosales MF,. Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks. J Clin Oncol. 2005; 23: 5983 – 92.
45. Llombart Cussac A, Baselga J, Manikhas G,. Phase II genomics study in patients receiving ixabepilone as neoadjuvant treatment for breast cancer (BC): preliminary efficacy and safety data. J Clin Oncol 2005; 23 (Suppl): 25s (Abstr 586).
46. Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger GG,. Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer. J Clin Oncol. 2009; 27: 526 – 34.
47. Ayers M, Symmans WF, Stec J, Damokosh AI, Clark E, Hess K,. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004; 22: 2284 – 93.
48. Saura C, Tseng L-M, Chan S, Chacko RT, Campone M, Liu D,. Phase 2 study of ixabepilone versus paclitaxel as neoadjuvant therapy for early stage breast cancer with comparative biomarker analysis. San Antonio Breast Cancer Symposium; 11 December 2010; San Antonio, TX, USA.
49. Rivera E, Lee J, Davies A. Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors. Oncologist. 2008; 13: 1207 – 23.
50. Horak CE, Pusztai L, Mudenda B, Xing G, Trifan O, Saura C,. B-III tubulin expression by immunohistochemistry (IHC) and mRNA in a randomized phase 2 neoadjuvant breast cancer (BC) study of ixabepilone (Ixa) compared to paclitaxel (pac). San Antonio Breast Cancer Symposium; 11 December 2010; San Antonio, TX, USA.
51. Hortobagyi GN, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF,. Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. Breast Cancer Res Treat. 2010; 122: 409 – 18.
52. Roche H, Conte P, Perez EA, Sparano JA, Xu B, Jassem J,. Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies. Breast Cancer Res Treat. 2011; 125: 755 – 65.
53. Fountzilas G, Dafni U, Dimopoulos MA, Koutras A, Skarlos D, Papakostas P,. A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. Breast Cancer Res Treat. 2009; 115: 87 – 99.
54. Abraham J, Agrawal M, Bakke S, Rutt A, Edgerly M, Balis FM,. Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. J Clin Oncol. 2003; 21: 1866 – 73.
55. Mani S, McDaid H, Hamilton A, Hochster H, Cohen MB, Khabelle D,. Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors. Clin Cancer Res. 2004; 10: 1289 – 98.
56. Gadgeel SM, Wozniak A, Boinpally RR, Wiegand R, Heilbrun LK, Jain V,. Phase I clinical trial of BMS-247550, a derivative of epothilone B, using accelerated titration 2B design. Clin Cancer Res. 2005; 11: 6233 – 9.
57. Zhuang SH, Agrawal M, Edgerly M, Bakke S, Kotz H, Thambi P,. A phase I clinical trial of ixabepilone (BMS-247550), an epothilone B analog, administered intravenously on a daily schedule for 3 days. Cancer. 2005; 103: 1932 – 8.
58. Shimizu T, Yamamoto N, Yamada Y, Fujisaka Y, Yamada K, Fujiwara Y,. Phase I clinical and pharmacokinetic study of 3-weekly, 3-h infusion of ixabepilone (BMS-247550), an epothilone B analog, in Japanese patients with refractory solid tumors. Cancer Chemother Pharmacol. 2008; 61: 751 – 8.
59. Denduluri N, Lee JJ, Walshe J, Berman AW, Vatas U, Chow CK,. Phase II trial of ixabepilone, an epothilone B analog, given daily for three days every three weeks, in metastatic breast cancer. Invest New Drugs. 2007; 25: 63 – 7.
60. Denduluri N, Low JA, Lee JJ, Berman AW, Walshe JM, Vatas U,. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes. J Clin Oncol. 2007; 25: 3421 – 7.
61. Rugo HS, Campone M, Amadori D, Wardley A, Villa E, Conte PF,. Randomized phase II study of weekly versus every-3-week ixabepilone plus bevacizumab (ixa/bev) versus paclitaxel plus bev (pac/bev) as first-line therapy for metastatic breast cancer (MBC). 2009 ASCO Annual Meeting; 2009: J Clin Onc.
62. Moulder S, Hailun L, Wang M, Gradishar WJ, Perez EA, Sparano JA,. A phase II trial of trastuzumab plus weekly ixabepilone and carboplatin in patients with HER2-positive metastatic breast cancer: an Eastern Cooperative Oncology Group Trial. Breast Cancer Res Treat. 2010; 119: 663 – 71.
63. Thomas ES, Gomez HL, Li RK, Chung HC, Fein LE, Chan VF,. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007; 25: 5210 – 7.
64. Sparano JA, Vrdoljak E, Rixe O, Xu B, Manikhas A, Medina C,. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2010; 28: 3256 – 63.